Cardiac rehabilitation reduces major adverse cardiac events and mortality in coronary artery disease patients after PCI

This meta-analysis examined the impact of cardiac rehabilitation on cardiovascular outcomes in patients with coronary artery disease following percutaneous coronary intervention. The study population comprised 115,177 individuals. The setting was not reported. The intervention involved cardiac rehabilitation, while the comparator was a control group. The analysis focused on primary and secondary cardiovascular endpoints to determine the efficacy of rehabilitation programs in this specific patient cohort.

The primary outcome assessed was major adverse cardiac events. The results indicated that these events were significantly lower in the cardiac rehabilitation group. The relative risk was 0.90 with a 95% confidence interval of 0.81 to 1.00 and a P value of 0.05. This suggests a modest but statistically significant reduction in the composite endpoint of major adverse cardiac events for patients undergoing rehabilitation compared to controls.

All-cause mortality was another critical primary outcome. The data demonstrated a significantly lower rate of death from any cause in the cardiac rehabilitation group. The relative risk was 0.69 with a 95% confidence interval of 0.57 to 0.84 and a P value of 0.0002. This represents a substantial reduction in mortality risk associated with participation in cardiac rehabilitation programs following percutaneous coronary intervention.

Secondary outcomes included heart failure, stable and unstable angina, arrhythmia, re-stenosis, cardiac death, and recurrent myocardial infarction. Heart failure rates were significantly lower in the rehabilitation group with a relative risk of 0.61 and a 95% confidence interval of 0.49 to 0.76. The P value for this outcome was 0.0001. Rates of stable and unstable angina were also significantly reduced with a relative risk of 0.30 and a 95% confidence interval of 0.18 to 0.49. The P value for this finding was 0.00001.

Arrhythmia incidence was significantly lower in the cardiac rehabilitation group with a relative risk of 0.70 and a 95% confidence interval of 0.61 to 0.81. The P value was 0.00001. For the outcomes of re-stenosis, cardiac death, and recurrent myocardial infarction, the results were similarly manifested. Specific effect sizes, absolute numbers, and confidence intervals were not reported for these specific endpoints in the available data.

Safety and tolerability findings were not reported in this analysis. Adverse events, serious adverse events, discontinuations, and general tolerability data were not provided. This lack of safety data is a notable gap in the evidence presented by this meta-analysis. The authors explicitly stated that there were several major limitations of this analysis. Funding sources and conflicts of interest were not reported.

These results compare favorably to prior landmark studies in the therapeutic area of cardiac rehabilitation, which have historically shown mixed results regarding mortality. This large pooled analysis provides stronger evidence for mortality reduction. However, the absence of detailed safety data and the presence of major limitations temper the certainty of these conclusions. The authors recommend that future larger trials should confirm the hypothesis that cardiac rehabilitation provides these benefits.

Clinically, this suggests that cardiac rehabilitation may be a valuable intervention for patients with coronary artery disease following percutaneous coronary intervention. The significant reduction in all-cause mortality and major adverse cardiac events supports the integration of such programs into standard care pathways. However, the lack of safety reporting means clinicians cannot fully assess the risk-benefit profile. Questions remain regarding the specific components of rehabilitation that drive these outcomes and the optimal duration of participation. The uncertainty around re-stenosis and recurrent myocardial infarction outcomes also warrants further investigation.